Drugs / Megace F
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01397214 | Jul → Sep 2011 | eating disorder, hypoproteinemia, hypercatabolic | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07168226 Comparator | May 2026 → Apr 2028 expected | hypoproteinemia, hypercatabolic | MetaFines | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Megace F | “Megace F suspension 625mg(5mL) administered daily in study 1” NCT07168226 ↗ |
| Route | Oral | “Megace F oral suspension” NCT01397214 ↗ |